Assessment of Neonatal Hyperbilirubinemia by NeoprediX B.1 Algorithm

NCT ID: NCT05121311

Last Updated: 2022-05-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

455 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-09

Study Completion Date

2022-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Due to actual standard of neonatal care bilirubin is monitored in neonates several times after birth to avoid hyperbilirubinemia. As the peak is often one or two days after discharge from hospital a more precise predication than the actual one is desirable to avoid needlessly follow-ups. The precision of an algorithm to predict bilirubin values 24-48h into the future is evaluated in this study.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neonatal jaundice is common and mostly transient without need for intervention. To identify infants at risk of bilirubin toxicity, bilirubin is measured several times after birth and before discharge home. As the peak bilirubin concentrations are reached at days 4-6 after birth, and most infants are discharged home around 48 hours after birth, parents are often asked to return to hospital one or two days after discharge with their newborn baby to have the bilirubin value checked in order to prevent that hyperbilirubinemia requiring treatment is not missed. A precise prediction of the course of bilirubin values based on the measurements done during the initial hospital stay after birth would be desirable to avoid unnecessary follow ups (both for the families and the health care system).

This study aims to evaluate the precision of the NeoprediX B1 algorithm. This algorithm predicts bilirubin values 24-48h into the future based on preceding values and some clinical variables. Five different scenarios will be explored, differing in the type, number and timepoints of measurements used for the prediction as well as the timepoint that is to be predicted.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Newborn Jaundice

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Newborns under bilirubin monitoring

Bilirubin monitoring according to standard of care of the participating center

NeoprediX B1 algorithm

Intervention Type DIAGNOSTIC_TEST

Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NeoprediX B1 algorithm

Re-assessement of bilirubin measurements done according to standard of care of the participating center by the NeoprediX B1 algorithm

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Newborn infant
* gestational age at birth ≥ 34+0/7 weeks

Exclusion Criteria

* Birth weight \< 1500g
* Gestational age at birth \> 42+6/7 weeks
* Genetically defined syndrome
* Severe congenital malformation adversely affecting life expectancy or admission for a priori planned palliative care
* Parents not fluent in German
Maximum Eligible Age

72 Hours

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Center for Pediatric Clinical Studies (CPCS)

UNKNOWN

Sponsor Role collaborator

NeoPredix AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Axel Franz, Prof.

Role: PRINCIPAL_INVESTIGATOR

University Children's Hospital Tübingen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KUNO Kinderklinik St. Hedwig

Regensburg, , Germany

Site Status

University Children's Hospital

Tübingen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

507/2021B02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Value of Transcutaneous Bilirubin Devices
NCT06232174 NOT_YET_RECRUITING
Transcutaneous Bilirubinometry and Phototherapy
NCT04246229 NOT_YET_RECRUITING NA
Hyperbilirubinemia in Full-term Neonates
NCT06238349 RECRUITING PHASE4